Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

Journal of Clinical Oncology

Volumn 21, Issue 1, 2003, Pages 123-128

  Beer, Tomasz M ^a,b   Eilers, Kristine M ^b   Garzotto, Mark ^b   Egorin, Merrill J ^b   Lowe, Bruce A ^b   Henner, W David ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; DOCETAXEL; DRUG DERIVATIVE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; TAXOID;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 0037208558     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/jco.2003.05.117     Document Type: Article

References (56)

1. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996.
2. Kantoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 17:2506-2513, 1999.
3. Picus J, Schultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 26:14-18, 1999.
4. Friedland D, Cohen J, Miller R Jr, et al: A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26:19-23, 1999.
5. Beer TM, Pierce WC, Lowe BA, et al: Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273-1279, 2001.
6. Berry W, Dakhil S, Gregurich MA, et al: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28:8-15, 2001.
7. Skowronski RJ, Peehl DM, Feldman D: Vitamin D and prostate cancer: 1, 25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960, 1993.
8. Peehl DM, Skowronski RJ, Leung GK, et al: Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 54:805-810, 1994.
9. Schwartz GG, Oeler TA, Uskokovic MR, et al: Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Res 14:1077-1081, 1994.
10. Skowronski RJ, Peehl DM, Feldman D: Actions of vitamin D3, analogs on human prostate cancer cell lines: Comparison with 1, 25- dihydroxyvitamin D3. Endocrinology 136:20-26, 1995.
11. Hedlund TE, Moffatt KA, Miller GJ: Vitamin D receptor expression is required for growth modulation by 1 alpha, 25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 58:277-288, 1996.
12. Zhuang SH, Schwartz GG, Cameron D, et al: Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83-90, 1997.
13. Getzenberg RH, Light BW, Lapco PE, et al: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50:999-1006, 1997.
14. Beer TM, Hough KM, Garzotto M, et al: Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 28:49-55, 2001.
15. Hershberger PA, Yu WD, Modzelewski RA, et al: Calcitriol (1, 25- dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043-1051, 2001.
16. Moffatt KA, Johannes WU, Miller GJ: 1Alpha, 25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5:695-703, 1999.
17. Campbell MJ, Koeffler HP: Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 89:182-185, 1997.
18. Liu M, Lee MH, Cohen M, et al: Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153, 1996.
19. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 271:1861-1864, 1996.
20. Kobayashi T, Hashimoto K, Yoshikawa K: Growth inhibition of human keratinocytes by 1, 25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product. Biochem Biophys Res Commun 196:487-493, 1993.
21. James SY, Mackay AG, Colston KW: Effects of 1, 25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Molec Biol 58:395-401, 1996.
22. Majewski S, Szmurlo A, Marczak M, et al: Inhibition of tumor cell-induced angiogenesis by retinoids, 1, 25-dihydroxyvitamin D3 and their combination. Cancer Lett 75:35-39, 1993.
23. Mantell DJ, Owens PE, Bundred NJ, et al: 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214-220, 2000.
24. Park WH, Seol JG, Kim ES, et al: Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol 109:576-583, 2000.
25. Tang W, Ziboh VA, Isseroff RR, et al: Novel regulatory actions of 1 alpha, 25-dihydroxyvitamin D3 on the metabolism of polyphosphoinositides in murine epidermal keratinocytes. J Cell Physiol 132:131-136, 1987.
26. Haugen JD, Pittelkow MR, Zinsmeister AR, et al: 1 alpha, 25- dihydroxyvitamin D3 inhibits normal human keratinocyte growth by increas- ing transforming growth factor beta 2 release. Biochem Biophys Res Commun 229:618-623, 1996.
27. Kim HJ, Abdelkader N, Katz M, et al: 1, 25-Dihydroxy-vitamin-D3 enhances antiproliferative effect and transcription of TGF-beta1 on human keratinocytes in culture. J Cell Physiol 151:579-587, 1992.
28. Vink-van Wijngaarden T, Pols HA, Buurman CJ, et al: Inhibition of insulin- And insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1, 25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. Eur J Cancer 32A:842-848, 1996.
29. Drivdahl RH, Loop SM, Andress DL, et al: IGF-binding proteins in human prostate tumor cells: Expression and regulation by 1, 25-dihydroxyvitamin D3. Prostate 26:72-79, 1995.
30. Yu WD, McGuire TF, Hershberger PA, et al: Paclitaxel enhances 1, 25-dihydroxyvitamin D3-induced apoptosis: Inhibition of survival signals and up-regulation of MEKK-1 and p73. Proc Am Assoc Cancer Res 43:434, 2002 (abstr).
31. Osborn JL, Schwartz GG, Smith DC, et al: Phase II trial of oral 1, 25-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer. Urol Oncol 1:195-198, 1995.
32. Gross C, Stamey T, Hancock S, et al: Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035- 2039, 1998.
33. Smith DC, Johnson CS, Freeman CC, et al: A phase I trial of calcitriol (1, 25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5:1339-1345, 1999.
34. Beer TM, Munar M, Henner WD: A phase I trial of pulse calcitriol in patients with refractory malignancies: Pulse dosing permits substantial dose escalation. Cancer 91:2431-2439, 2001.
35. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999.
36. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States. National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000.
37. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989.
38. Blanke CD, Stipanov M, Morrow J, et al: A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies. Invest New Drugs 19:21-27, 2001.
39. Hollis BW, Kamerud JQ, Kurkowski A, et al: Quantification of circulating 1, 25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer. Clin Chem 42:586-592, 1996.
40. Garg MB, Ackland SP: Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J Chromatogr B Biomed Sci Appl 748:383-388, 2000.
41. Yu WD, McElwain MC, Modzelewski RA, et al: Enhancement of 1, 25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 90:134-141, 1998.
42. Bernardi RJ, Trump DL, Yu WD, et al: Combination of 1alpha, 25- dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 7:4164-4173, 2001.
43. Colston KW, Chander SK, Mackay AG, et al: Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693-702, 1992.
44. Higashimoto Y, Ohata M, Nishio K, et al: 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res 16:2653-2659, 1996.
45. Konety BR, Lavelle JP, Pirtskalaishvili G, et al: Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 165:253-258, 2001.
46. Cross HS, Huber C, Peterlik M: Antiproliferative effect of 1, 25- dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2): Influence of extracellular calcium. Biochem Biophys Res Commun 179:57-62, 1991.
47. Zugmaier G, Jager R, Grage B, et al: Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer 73:1341-1346, 1996.
48. Yabushita H, Hirata M, Noguchi M, et al: Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1, 25- dihydroxyvitamin D3 on endometrial carcinoma cell lines. J Obstet Gynaecol Res 22:529-539, 1996.
49. Abe E, Miyaura C, Sakagami H, et al: Differentiation of mouse myeloid leukemia cells induced by 1 alpha, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 78:4990-4994, 1981.
50. Colston K, Colston MJ, Feldman D: 1, 25-dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology 108:1083-1086, 1981.
51. Shabahang M, Buffan AE, Nolla JM, et al: The effect of 1, 25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor. Ann Surg Oncol 3:144-149, 1996.
52. Tokuumi Y: [Correlation between the concentration of 1, 25 alpha dihydroxyvitamin D3 receptors and growth inhibition, and differentiation of human osteosarcoma cells induced by vitamin D3]. Nippon Seikeigeka Gakkai Zasshi 69:181-190, 1995.
53. Light BW, Yu WD, McElwain MC, et al: Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57:3759-3764, 1997.
54. Wieder R, Wang Q, Uytingco M, et al: 1, 25-dihydroxyvitamin D3 and all-trans retinoic acid promote apoptosis and sensitize breast cancer cells to the effects of chemotherapeutic agents. Proc ASCO 17:107a, 1998 (abstr).
55. Sundaram S, Chaudhry M, Reardon D, et al: The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat 63:1-10, 2000.
56. Torres R, Calle C, Aller P, et al: Etoposide stimulates 1, 25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells. Mol Cell Biochem 208:157-162, 2000.